References
- Mzingwane ML , TiemessenCT . Mechanisms of HIV persistence in HIV reservoirs . Rev. Med. Virol.27 ( 2 ), doi:10.1002/rmv.1924 ( 2017 ) ( Epub ahead of print ).
- Ocque AJ , HaglerCE, DifrancescoRet al. Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver . Bioanalysis8 ( 13 ), 1353 – 1363 ( 2016 ).
- Policicchio BB , PandreaI, ApetreiC . Animal models for HIV cure research . Front. Immunol.7, 12 ( 2016 ).
- Archin NM , SungJM, GarridoC, Soriano-SarabiaN, MargolisDM . Eradicating HIV-1 infection: seeking to clear a persistent pathogen . Nat. Rev. Microbiol.12 ( 11 ), 750 – 764 ( 2014 ).
- Rasmussen TA , Schmeltz SogaardO, BrinkmannCet al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation . Hum. Vaccin. Immunother.9 ( 5 ), 993 – 1001 ( 2013 ).
- Ethirajulu K , RameshJ . Histone deacetylase inhibitors as therapeutic agents for cancer therapy: drug metabolism and pharmacokinetic properties . In : Drug Development – A Case Study Based Insight into Modern Strategies . RundfeldtC ( Ed. ). InTech, Rijeka, Croatia ( 2011 ).
- Bar KJ , SnellerMC, HarrisonLJet al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption . N. Engl. J. Med.375 ( 21 ), 2037 – 2050 ( 2016 ).
- Jacobson JM , ZhengL, WilsonCCet al. The safety and immunogenicity of an interleukin-12-enhanced multiantigen DNA vaccine delivered by electroporation for the treatment of HIV-1 infection . J. Acquir. Immune Defic. Syndr.71 ( 2 ), 163 – 171 ( 2016 ).
- Gay CL , BoschRJ, RitzJet al. Clinical trial of the Anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy . J. Infect. Dis.215 ( 11 ), 1725 – 1733 ( 2017 ).
- Edagwa BJ , ZhouT, McmillanJM, LiuXM, GendelmanHE . Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies . Curr. Med. Chem.21 ( 36 ), 4186 – 4198 ( 2014 ).
- Guo D , ZhangG, WysockiTAet al. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance . J. Virol.88 ( 17 ), 9504 – 9513 ( 2014 ).
- U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research . Guidance for industry: population pharmacokinetics . Draft Guidance for Industry ( 1999 ). www.fda.gov/downloads/drugs/guidances/UCM072137.pdf .
- U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research . Physiologically based pharmacokinetic analyses – format and content, draft guidance for industry ( 2006 ). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM531207.pdf .
- Mager DE , WyskaE, JuskoWJ . Diversity of mechanism-based pharmacodynamic models . Drug Metab. Dispos.31 ( 5 ), 510 – 518 ( 2003 ).